Human Genome Bill Sponsor Pulls Back, Shifts Tactics

WASHINGTON—One of the most frequent complaints about Congress is how long it takes to get something done. Last month Sen. Pete Domenici (R-N.M.) found out that trying to move too fast may be an even bigger problem. On July 10 Domenici introduced a bill (S. 1480) to create a federal advisory board and governmentuniversity-industry consortium to map and sequence the human genome. The bill, which would have set up cooperative research efforts on semiconductors and superconducting materials

Written byJeffrey Mervis
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

WASHINGTON—One of the most frequent complaints about Congress is how long it takes to get something done. Last month Sen. Pete Domenici (R-N.M.) found out that trying to move too fast may be an even bigger problem.

On July 10 Domenici introduced a bill (S. 1480) to create a federal advisory board and governmentuniversity-industry consortium to map and sequence the human genome. The bill, which would have set up cooperative research efforts on semiconductors and superconducting materials as well, gave a starring role to the Department of Energy’s national laboratories. Dispensing with committee hearings, the former chairman of the Senate Budget Committee was poised July 21 to offer his bill as an amendment to the Omnibus Trade Act being voted on by the Senate.

It was no surprise that Domenici, who represents a state that is home to Los Alamos and Sandia national laboratories, would favor DOE. And he probably ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies